Alzheimer's Disease
Advisory Board
Alireza Atri, MD, PhD
Chief Medical Officer, Banner Research, Banner Alzheimer's Institute (Phoenix and Tucson); Director, Banner Sun Health Research Institute, Banner Health, Sun City, Arizona; Lecturer on Neurology, Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Dr Atri is a cognitive neurologist, neuroscientist, clinical researcher, and educator. He specializes in Alzheimer's disease and related dementias, with a focus on improving detection, reducing risk, and developing best clinical practices. He also specializes in caring for people with early-stage and early-onset cognitive disorders and young-onset Alzheimer's and related dementias.
Dr Atri's leadership roles have included co-chair of the US Alzheimer's Association's national clinical practice guidelines workgroup; chair of the Alzheimer's Disease International Medical Scientific Advisory Panel; and Project Arm Leader for the Dominantly Inherited Alzheimer's Network–Trials Unit. Additionally, Dr Atri serves on several steering committees of global Alzheimer's experimental trials programs.
Disclosures
Alireza Atri, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AriBio; Eisai; Lundbeck; Merck; Novo Nordisk; Prothena
Received research grant from: Consortia (ACTC, ADCS); NIH; FNIH; AZ DHS; Gates Ventures; Athira; Alzheon; Eisai; Vivoryon Therapeutics; Washington University in St Louis; Johns Hopkins.
Received income in an amount equal to or greater than $250 from: Oxford University Press
James E. Galvin, MD, MPH
Professor of Neurology, Psychiatry and Behavioral Sciences; Chief, Division of Cognitive Neurology; Director, Comprehensive Center for Brain Health, Miller School of Medicine, University of Miami, Miami, Florida
Dr Galvin, a board-certified neurologist, specializes in brain health, cognitive aging, Alzheimer's disease, Lewy body dementia, and related disorders. His research focus includes the development of novel approaches for studying brain health and cognitive impairment, addressing health disparities, and exploring root causes of neurodegenerative diseases.
Dr Galvin is principal investigator on multiple National Institutes of Health grants. The focus of his team's research is clinical, cognitive, and behavioral features of healthy brain aging and neurodegenerative diseases. As founding director of the Comprehensive Center for Brain Health, Dr Galvin spearheads transdisciplinary research combining neurology, gerontology, and cognitive neuroscience. He leads a multidisciplinary team investigating features of healthy brain aging and neurodegenerative disease, and their relationship to novel biomarkers of brain pathology.
Disclosures
James E. Galvin, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Biogen; BMS; Cognivue; Eisai; Eli Lilly; Genentech; GE HealthCare; Lundbeck; Roche
Aimee L. Pierce, MD
Associate Professor of Neurology; Director, Clinical Care and Therapeutics Program, Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University, Portland, Oregon
Dr Pierce specializes in memory loss and dementia diagnosis, treatment, and prevention, particularly Alzheimer's disease and related conditions, such as vascular dementia, frontotemporal dementia, Lewy body dementia, and Parkinson's disease dementia. She is dedicated to early detection and uses a combination of advanced diagnostics, including blood biomarker testing, genetic testing, neuropsychological testing, MRI, PET (FDG-PET, amyloid-PET, and tau PET), and cerebrospinal fluid analysis, to support diagnostic accuracy.
Dr Pierce has led multiple clinical trials investigating potential new treatment strategies, such as immunotherapy; has contributed to numerous publications in the field; and is recognized for her contributions to Alzheimer's research.
Disclosures
Aimee L. Pierce, MD, has disclosed the following relevant financial relationships:
Received research grant from: Alector; Cognition Therapeutics; Eisai; Eli Lilly; Roche; Vivoryon